Abbott Receives CE Marking for Esprit BTK System: A Breakthrough in Peripheral Artery Disease Treatment.

Abbott has received CE marking for the Esprit BTK System, a resorbable everolimus-eluting stent for below-the-knee peripheral artery disease. The system is made of a dissolving material and improves patient outcomes, reducing repeat procedures by 48%. It is designed to keep arteries open and deliver a drug to promote vessel healing before dissolving completely over time. The Esprit BTK System addresses a significant unmet need for patients with severe PAD below the knee.